UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2006 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO _________ COMMISSION FILE NUMBER: 000-25132 MYMETICS CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 25-1741849 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) European Executive Office 14, rue de la Colombiere 1260 Nyon (Switzerland) (Address of principal executive offices) 011 41 22 363 13 10 (Registrant's telephone number, including area code) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [X] Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No X --- --- Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date: Class Outstanding at November 4, 2006 ----- ------------------------------- Common Stock, $0.01 105,170,464 par value PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS MYMETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED BALANCE SHEETS (UNAUDITED) (IN THOUSANDS OF EUROS) September 30, December 31, 2006 2005 ------------ ------------ ASSETS Current Assets Cash E 45 E 70 Receivables 62 42 Prepaid expenses 0 2 -------- -------- Total current assets 107 114 Patents 352 52 -------- -------- E 459 E 166 ======== ======== LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable E 2,227 E 2,095 Taxes and social costs payable 15 15 Current portion of notes payable 4,298 3,754 Other 288 301 -------- -------- Total current liabilities 6,828 6,165 Payable to Shareholders 242 242 Note Payable, less current portion -- 39 -------- -------- Total liabilities 7,070 6,446 Shareholders' Equity (Deficit) Common stock, U.S. $.01 par value; 495,000,000 shares authorized; issued and outstanding 105,170,464 at September 30, 2006 and 82,670,464 at December 31, 2005 1,018 778 Common stock issuable; 600,000 shares -- 59 Preferred stock, U.S. $.01 par value; 5,000,000 shares authorized; none issued or outstanding -- -- Additional paid-in capital 6,991 6,227 Deficit accumulated during the development stage (15,377) (14,087) Accumulated other comprehensive income 757 743 -------- -------- (6,611) (6,280) -------- -------- E 459 E 166 ======== ======== The accompanying notes are an integral part of these financial statements. MYMETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (IN THOUSANDS OF EUROS, EXCEPT FOR PER SHARE AMOUNTS) FOR THE NINE FOR THE NINE TOTAL ACCUMULATED MONTHS ENDED MONTHS ENDED DURING THE SEPTEMBER 30, 2006 SEPTEMBER 30, 2005 DEVELOPMENT STAGE ------------------ ------------------ ----------------- Revenue Sales E -- E -- E 224 Interest -- -- 34 -------- -------- -------- -- -- 258 -------- -------- -------- Expenses Research and development 468 340 5,554 General and administrative 622 904 7,022 Bank fee -- -- 935 Interest 125 164 1,089 Goodwill impairment -- -- 209 Amortization 75 55 536 Directors' fees -- -- 274 Other -- -- 10 -------- -------- -------- 1,290 1,463 15,629 -------- -------- -------- Loss before income tax provision (1,290) (1,463) (15,371) Income tax provision -- -- (6) -------- -------- -------- Net loss (1,290) (1,463) (15,377) Other comprehensive income Foreign currency translation adjustment 14 (94) 757 -------- -------- -------- Comprehensive loss E (1,276) E (1,557) E(14,620) ======== ======== ======== Basic and diluted loss per share E (0.01) E (0.02) ======== ======== The accompanying notes are an integral part of these financial statements. MYMETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (IN THOUSANDS OF EUROS, EXCEPT FOR PER SHARE AMOUNTS) FOR THE THREE FOR THE THREE MONTHS ENDED MONTHS ENDED SEPTEMBER 30, 2006 SEPTEMBER 30, 2005 ------------------ ------------------ Revenue Sales E -- E -- Interest -- -- -------- -------- -- -- -------- -------- Expenses Research and development 149 (30) General and administrative 361 261 Bank fee -- -- Interest -- 56 Goodwill impairment -- -- Amortization 25 25 Directors' fees -- -- Other -- -- -------- -------- 535 312 -------- -------- Loss before income tax provision (535) (312) Income tax provision -- -- -------- -------- Net loss (535) (312) Other comprehensive income Foreign currency translation adjustment (6) (27) -------- -------- Comprehensive loss E (541) E (339) ======== ======== Basic and diluted loss per share E (0.01) E (0.00) ======== ======== The accompanying notes are an integral part of these financial statements. MYMETICS CORPORATION (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (IN THOUSANDS OF EUROS) FOR THE NINE FOR THE NINE TOTAL ACCUMULATED MONTHS ENDED MONTHS ENDED DURING THE SEPTEMBER 30, 2006 SEPTEMBER 30, 2005 DEVELOPMENT STAGE ------------------ ------------------ ----------------- Cash flow from operating activities Net Loss E (1,290) E (1,463) E (15,377) Adjustments to reconcile net loss to net cash used in operating activities Amortization 75 55 536 Goodwill impairment -- -- 209 Fees paid in warrants -- -- 223 Services and fee paid in common stock -- 441 1,928 Amortization of debt discount -- -- 210 Changes in current assets and liabilities, net of effects from reverse purchase Decrease(increase) in receivables (20) 42 (24) Increase(decrease) in accounts payable 132 631 1,929 Increase(decrease) in taxes and -- -- 15 social costs payable Increase(decrease) in other (11) -- 336 -------- -------- -------- Net cash used in operating activities (1,114) (294) (10,015) -------- -------- -------- Cash flows from investing activities Patents and other (375) (48) (768) Cash acquired in reverse purchase -- -- 13 -------- -------- -------- Net cash used in investing activities (375) (48) (755) -------- -------- -------- Cash flows from financing activities Proceeds from issuance of common stock 945 70 4,964 Borrowing from shareholders -- -- 242 Increase in note payable and other short-term advances 505 366 4,982 Loan fees -- -- (130) -------- -------- -------- Net cash provided by financing activities 1,450 436 10,058 -------- -------- -------- Effect on foreign exchange rate on cash 14 (94) 757 -------- -------- -------- Net change in cash (25) -- 45 Cash, beginning of period 70 -- -- -------- -------- -------- Cash, end of period E 45 E -- E 45 ======== ======== ======== The accompanying notes are an integral part of these financial statements. MYMETICS CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2006 (UNAUDITED) Note 1. The Company and Summary of Significant Accounting Policies Basis of Presentation The accompanying interim period consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2005. The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three- and nine-month periods ended September 30, 2006 were of a normal and recurring nature. The amounts presented for the three- and nine-month periods ended September 30, 2006, are not necessarily indicative of the results of operations for a full year. The amounts in the notes are rounded to the nearest thousand of Euros except for per share amounts. The Company was created for the purpose of engaging in research and development of human health products. Its main research efforts have been concentrated in the prevention and treatment of the HIV-AIDS virus. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. These financial statements have been prepared treating the Company as a development stage company. As of September 30, 2006, the Company had not performed any human clinical testing and revenues obtained from the sale or licensing of the Company's technology are not expected before 2007 at the earliest. As such, the Company has not generated significant revenues. Revenues reported by the Company consist of incidental serum by-products of the Company's research and development activities and interest income. For the purpose of these financial statements, the development stage started May 2, 1990. These financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in a deficit in shareholders' equity (deficit) of E6,611 at September 30, 2006. Deficits in operating cash flows since inception have been financed through debt and equity funding sources. In order to remain a going concern and continue the Company's research and development activities, management intends to seek additional funding. Further, the Company's current liabilities exceed its current assets by E6,370 as of September 30, 2006, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated. Foreign Currency Translation The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the year. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe. Receivables Receivables are stated at their outstanding principal balances. Management reviews the collectibility of receivables on a periodic basis and determines the appropriate amount of any allowance. Based on this review procedure, management has determined that the allowances at September 30, 2006 and December 31, 2005 are sufficient. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. Current liabilities The Company was not able to meet the E900,000 loan repayment due at September 30, 2006 to MFC Merchant SA ("MFC") under its E3.7 million credit facility. MFC had initially agreed to delay declaring a default to allow MFC and the Company to negotiate terms of repayment acceptable to MFC, and for the Company to identify additional investors to fund the repayment, which it did. On September 1, 2006, the Company received a letter from MFC declaring the Company in default. Under the terms of the credit facility, the Company's default accelerates the repayment of the credit facility. In its letter, MFC demanded repayment no later than September 5, 2006 of the total outstanding balance under the credit facility, totaling approximately E3.9 million including interest through such date. The Company has not made that repayment. In response to the prior threats of MFC to declare the Company in default of the above credit facility and receipt of the September 1, 2006 letter from MFC described above, the Company proceeded with lawsuits in Delaware and New York against MFC, Michael J. Smith, John M. Musacchio and Michael K. Allio, personally, and KHD Humboldt Wedag International, Ltd. (f/k/a MFCBancorp., Ltd.) alleging breaches of fiduciary duty, interference with prospective business relations and civil conspiracy against one or more of the foregoing parties. The Company believes that it has valid grounds to contest the validity of the credit facility with MFC and intends to defend itself vigorously against MFC's efforts to foreclose on the loan. Research and Development Research and development costs are expensed as incurred. Taxes on Income The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates. Earnings per Share Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding in the period. The weighted average number of shares was 104,409,594 and 72,032,474 for the three months ended September 30, 2006 and 2005, respectively. The weighted average number of shares was 104,409,594 and 70,591,953 for the nine months ended September 30, 2006 and 2005, respectively. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. Warrants and options were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred. Stock-Based Compensation As of January 1, 2006, the Company adopted SFAS No. 123(R) using the modified prospective method, which requires measurement of compensation cost for all stock-based awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes valuation model, which is consistent with the Company's valuation techniques previously utilized for options in footnote disclosures required under SFAS No. 123, Accounting for Stock Based Compensation, as amended by SFAS No. 148, Accounting for Stock-Based Compensation--Transition and Disclosure. Since the Company did not issue stock options to employees during the three months ended September 30, 2006 or 2005, there is no effect on net loss or earnings per share had the Company applied the fair value recognition provisions of SFAS No. 123(R) to stock-based employee compensation. When the Company issues shares of common stock to employees and others, the shares of common stock are valued based on the market price at the date the shares of common stock are approved for issuance. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS GENERAL The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation for the periods ended September 30, 2006 and 2005 should be read in conjunction with the Company's audited consolidated financial statements and related notes and the description of the Company's business and properties included elsewhere herein. This report contains forward-looking statements that involve risks and uncertainties. The statements contained in this report are not purely historical, but are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue", "probably" or similar words are intended to identify forward looking statements, although not all forward looking statements contain these words. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after the date hereof to conform such statements to actual results or to changes in our expectations. Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in our annual report on Form 10-K for the year ended December 31, 2005 and, to the extent included therein, our quarterly reports on Form 10-Q filed during fiscal year 2006. NINE MONTHS ENDED SEPTEMBER 30, 2006 AND 2005 Revenue was nil for the nine months ended September 30, 2006 and September 30, 2005. Costs and expenses decreased to E1,290,000 for the nine months ended September 30, 2006 from E1,463,000 (-11.8%) for the nine months ended September 30, 2005. Research and development expenses increased to E468,000 in the current period from E340,000 (37.6%) in the comparative period of 2005 as we are now preparing the viral challenge tests of our immunized non-human primates. General and administrative expenses decreased to E622,000 in the nine months ended September 30, 2006 from E904,000 in the comparative period of 2005 (-31.2%) mostly due to overall cost reduction measures and the fact that the comparative period of 2005 included the cost of 1,500,000 shares issued to an affiliate of MFC under pressure from MFC. The Company reported a net loss of E1,290,000, or E0.01 per share, for the nine months ended September 30, 2006, compared to a net loss of E1,463,000, or E0.01, for the nine months ended September 30, 2005. LIQUIDITY AND CAPITAL RESOURCES The Company had cash of E45,000 at September 30, 2006 compared to E70,000 at December 31, 2005. We have not generated any material revenues since we commenced our current line of business in 2001, and we do not anticipate generating any material revenues on a sustained basis unless and until a licensing agreement or other commercial arrangement is entered into with respect to our technology. Increases in borrowing provided cash of E505,000 in the current period, of which E200,000 came from one of our shareholders and the balance pursuant to a non-revolving term facility compared to E366,000 during the nine months ended September 30, 2005. The non-revolving term facility is in the principal amount of up to E3.7 million and was to mature on December 31, 2006 before the Company was declared in default by MFC. At September 30, 2006, Mymetics had borrowed an aggregate of E3,947,000 pursuant to this non-revolving term facility. As of September 30, 2006, we had an accumulated deficit of approximately E15.4 million, and we incurred losses of E1,290,000 in the nine-month period ending on that date. These losses are principally associated with the research and development of our HIV vaccine technologies. We expect to continue to incur expenses in the future for research, development and activities related to the future licensing of our technologies. Accounts payable of E2,227,000 at September 30, 2006, include E353,000 due to our officers as unpaid salaries, fees and out-of-pocket expenses, after E292,000 has been converted into restricted shares of our common stock at $0.10 per share for a total of 3,500,000 shares, on July 20, 2006. The E242,000 payable to shareholders at September 30, 2006, represents various amounts advanced by a shareholder and former director to Hippocampe S.A. (now Mymetics S.A., our French affiliate) between 1990 and 1999. These advances are reimbursable subject to the French legal concept of "retour a meilleure fortune", or literally, "return to better times," which means when the Company's financial status improves so that repayment is possible. This ambiguous concept has been contractually defined in November 1998 between the lender and Aralis Participations S.A., then a major shareholder of Hippocampe S.A., as essentially a positive working capital ratio of 1.2 during four consecutive quarters, said ratio to be computed exclusively on the basis of commercial revenues for Hippocampe S.A., i.e., to the exclusion of subsidies, whether from related or unrelated parties. Considering the present status of Mymetics S.A., it is impossible to predict when such amounts will be reimbursed to the lender, if at all. Consequently, they are classified as long term debts. Because our French subsidiary is in receivership (as disclosed in our Form 8-K dated February 13, 2006), Mymetics SA cannot return to "better times" so long as the collection efforts of Dr. Serres force the Company to remain in receivership. Consequently, this amount will never have to be repaid, and we most probably will have to reverse it as soon as the French courts close the Mymetics SA file. Net cash used in operating activities was E1,114,000 for the period ended September 30, 2006, compared to E294,000 for the period ended September 30, 2005, due mostly to an increase in Accounts Payable of E132,000. Investing activities used E375,000 during the nine months ended September 30, 2006, entirely in the application of new patents, as compared to E48,000 used during the nine months ended September 30, 2005. Financing activities provided cash of E1,450,000 for the period ended September 30, 2006 compared to E436,000 in the same period last year. Proceeds from issuance of common stock provided E945,000 during the period ended September 30, 2006 compared to E70,000 in the same period in 2005. Salaries and related payroll costs represent fees for all of our directors other than our employee directors, gross salaries for two of our executive officers, and payments under consulting contracts with two of our officers. We do not pay our non-employee directors, and we credit our salaried executive officers a combined amount of E54,000 per month under an informal agreement approved by our Board of Directors in 2003 until June 30, 2006. On July 1, 2006, the Board of Directors approved formal Executive Employment Agreements with our CEO, CFO and CSO. Since January 15, 2004, payments of E4,000 per month for Professor Marc Girard's services as our Head of Vaccines Development were due pursuant to a consulting agreement dated June 10, 2004, as disclosed in our filing on Form 10-Q for the period ended September 30, 2004 to the Securities and Exchange Commission. We have not been able to make the payments due under the agreement on a regular basis, and we owed Professor Girard approximately E59,000 at September 30, 2006, after conversion of E40,000 into restricted shares of the Company's common stock at $0.10 per share (resulting in our issuance to Professor Girard of 500,000 shares of our common stock). Monthly fixed and recurring expenses for "Property leases" of E1,000 represents the monthly lease and maintenance payments to unaffiliated third parties for our executive offices located at 14, rue de la Colombiere in Nyon (Switzerland) (600 square feet), which can be cancelled on one month notice. We do not lease any research facilities since Dr. Fleury's facilities were provided free of charge until June 30, 2006 by CHUV. As a temporary measure following the termination of our agreement with CHUV, we have leased minimal office facilities for Dr. Fleury starting August 15, 2006 at a monthly cost of E1,000, which includes full access to medical databases over high speed internet connection. This lease can be cancelled on very short term notice as we are planning to lease in the next few months facilities on the campus of the Swiss Federal Institute of Technology (EPFL) in Lausanne (Switzerland), located 15 miles from our Nyon office, including laboratory facilities to conduct quality checks and to verify scientific results. Included in professional fees are estimated recurring legal fees paid to outside corporate counsel and ongoing litigation expenses, audit and review fees paid to our independent accountants, and fees paid for investor relations. Interest expense represents interest paid to MFC Merchant Bank S.A. for a note payable. This note payable in the maximum principal amount of E3.7 million carries an interest rate of Libor + 4% which is accrued on a quarterly basis. As of September 30, 2006, we had three full-time salaried executives, exclusive of our contracts for the consulting services of Professor Girard, our Head of Vaccines Development. Certain secretarial work for our CEO is outsourced to self-employed secretaries who accept being partially paid in common stock of Mymetics at the current market price. We anticipate hiring an assistant to our CFO as well as a part-time laboratory technician in the first half of 2007, and may need to hire additional personnel to meet the needs and demands of any future workload. We intend to continue to incur additional expenditures during the next 12 months for additional research and development of our HIV vaccines. These expenditures will relate to the continued gp41 testing and are included in the monthly cash outflow described above. Additional funding requirements during the next 12 months may arise upon the commencement of a phase I clinical trial. We expect that funding for the cost of any clinical trials would be available either from debt or equity financings, donors and/or potential pharmaceutical partners before we commence the human trials. In the past we have financed our research and development activities primarily through debt and equity financings from various parties. The Company anticipates its operations will require approximately E6 million until December 31, 2007. An additional E2 million will be needed either to settle or to litigate the MFC case. The Company will seek to raise the required capital from equity or debt financings, donors and/or potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that the Company will be able to raise additional capital on terms satisfactory to the Company, or at all, to finance its operations. In the event that the Company is not able to obtain such additional capital, it would be required to further restrict or even halt its operations. RECENT FINANCING ACTIVITIES To date we have generated no material revenues from our business operations. We are unable to predict when or if we will be able to generate revenues from licensing our technology or the amounts expected from such activities. These revenue streams may be generated by us or in conjunction with collaborative partners or third party licensing arrangements, and may include provisions for one-time, lump sum payments in addition to ongoing royalty payments or other revenue sharing arrangements. However, we presently have no commitments for any such payments. Sources of additional capital include funding through future collaborative arrangements, licensing arrangements, and debt and equity financings. We do not know whether additional financing will be available on commercially acceptable terms when needed. If we cannot raise funds on acceptable terms when needed, we may not be able to successfully commercialize our technologies, take advantage of future opportunities, or respond to unanticipated requirements. If we are unable to secure such additional financing when needed, we will have to curtail or suspend all or a portion of our business activities and we could be required to cease operations entirely. Further, if we issue equity securities, our shareholders may experience severe dilution of their ownership percentage. We are presently engaged in raising the equivalent of E8 million from Swiss investors under Regulation S under the Securities Act of 1933 in the form of Convertible Notes at staggered conversion prices between $0.10 and $0.60 (depending on the date committed). This method was preferred to straight sales of shares at current market price as we and our new investors believe that the market price presently does not accurately reflect the value of our common stock but only reflects our past and the difficulty we face in communicating our results to the public due to the complex scientific issues involved and the requirements of secrecy under patent laws, which preclude us from communicating our latest results until the relevant patent applications become public eighteen months after filing. We anticipate using our current funds and those we receive in the future both to meet our working capital needs and for funding the ongoing research costs associated with our gp41 testing. Provided we can obtain sufficient financing resources, we expect to begin phase I clinical trials in 2007. In accordance with our past strategy, we intend to subcontract such work to "best of class" research teams unless institutions such as the US National Institutes of Health (NIH) or the French CEA decide to conduct it at their own expenses, which they presently do. We do not anticipate that our existing capital resources will be sufficient to fund our cash requirements through the next three months. We do not have enough cash presently on hand, based upon our current levels of expenditures and anticipated needs during this period, and we will need additional proceeds from additional equity investments such as private placements under Regulation D and Regulation S under the Securities Act of 1933. The extent and timing of our future capital requirements will depend primarily upon the rate of our progress in the research and development of our technologies, our ability to enter into a partnership agreement with a major pharmaceutical company, and the results of future clinical trials. Our early attempts at attracting grants from humanitarian donors have not been successful because such donors are usually barred from making donations to for-profit and/or publicly traded companies such as Mymetics. In addition, most humanitarian donors demand that grant recipients abandon their intellectual property rights or alternatively, severely limit their commercial margins on the sale of preventive vaccines in the developing world. Based on the discussions we have had so far with major pharmaceutical companies in view of entering into a partnership agreement, it is obvious that these potential partners are not thrilled by the prospect of having to limit their margins in the developing world. Therefore and in order to become both eligible for grants and attractive to potential partners, the Company has decided to create (or enter into an agreement with an existing) non-profit foundation to which our intellectual property related to HIV Clade C will be granted free of charge through a cross-licensing agreement. HIV Clade C is the form of HIV virus prevalent in Africa and other developing countries, mostly in Asia. Mymetics will retain all intellectual property related to Clade B, the form of HIV virus prevalent in Europe and North America. Under this scheme, the foundation will be eligible for humanitarian grants to further R&D specifically aimed at developing countries while the prospect of having to cope with a low margin distribution of vaccine in such countries will not hamper our forthcoming negotiations with major pharmaceutical companies to which will only be able to offer Clade B based technology for distribution in high-yield markets such as Europe and North America. OFF-BALANCE SHEET ARRANGEMENTS The Company does not have any off-balance sheet arrangements. TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS PAYMENTS DUE BY PERIOD (THOUSANDS OF EUROS) CONTRACTUAL OBLIGATION TOTAL LESS 1 - 3 3 - 5 MORE THAN YEARS YEARS THAN 1 YEAR 5 YEARS Long-term debt E0 E0 E0 E0 E0 Capital Lease Obligations E0 E0 E0 E0 E0 Operating Lease Obligations E0 E0 E0 E0 E0 Purchase Obligations E610 (1,2) E600 E10 E0 E0 Other Long-Term Liabilities Reflected on E242 (3) E0 E0 E0 E242 Mymetics Balance Sheet under GAAP TOTAL E852 E600 E10 E0 E242 (1) Represents various amounts due to suppliers and partners in respect of the forthcoming human clinical trials phase I scheduled for 2007. (2) French auditors ("Commissaire aux Comptes") are elected for 6 years and cannot be terminated. Our French auditor was re-elected in 2003. Based on current budget and cost estimates, we posted E5,000 per year for the audits 2006 and 2007, when we expect the French company to be dissolved. (3) Due to P.-F. Serres, one of our former directors, repayable only after certain conditions related to our French subsidiary's financial situation have been met. Because of Dr. Serres' legal action against our French subsidiary which resulted in the latter being put under receivership ("Redressement judiciaire"), it is highly unlikely that these conditions will ever be met and therefore that we will ever have to repay Dr. Serres. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are exposed to market risk from changes in interest rates which could affect our financial condition and results of operations. We have not entered into derivative contracts for our own account to hedge against such risk. INTEREST RATE RISK Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have debt obligations which are sensitive to interest rate fluctuations. ITEM 4. CONTROLS AND PROCEDURES Disclosure Controls and Procedures. As of the end of the registrant's fiscal year ended December 31, 2005, an evaluation of the effectiveness of the registrant's "disclosure controls and procedures" (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) was carried out by the registrant's principal executive officer and principal financial officer. Based upon that evaluation, the registrant's principal executive officer and principal financial officer have concluded that as of the end of that fiscal year, the registrant's disclosure controls and procedures are effective to ensure that information required to be disclosed by the registrant in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. It should be noted that while the registrant's principal executive officer and principal financial officer believe that the registrant's disclosure controls and procedures provide a reasonable level of assurance that they are effective, they do not expect that the registrant's disclosure controls and procedures or internal control over financial reporting will prevent all errors and fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS On October 26, 2006, the Court of Appeals of Lyon (France) invalidated a judgement rendered by the Lyon Industrial Tribunal ("Prud'hommes") in favor of Dr. Pierre-Francois Serres, a former director and officer of the Company. Under this lower court judgement and as disclosed on form 10-K for the year ended December 31, 2005 to the Securities and Exchange Commission, Dr. Serres was awarded approximately E173,000, of which E100,000 was payable immediately, i.e. without suspensive effect due to the appeal we filed on December 14, 2005. In the appeal judgement now rendered, the Court of Appeals qualified as "fictitious" the employment agreement presented to the lower court by Dr. Serres as the heart of his case against Mymetics SA. As a result, Dr. Serres not only suffered a complete defeat but was also condemned to make certain reparatory payments to Mymetics SA. In addition, Dr. Serres will have to reimburse approximately E33,000 he had previously been able to seize on the company's bank account based on the lower court's initial judgement. We intend to vigorously pursue this matter until fully resolved. By way of background, Dr. Serres was terminated by the Company's previous management and later reinstated by existing management as Chief Scientific Officer retroactively commencing May 5, 2003. In November 2003 Dr. Serres was appointed Head of Exploratory Research. Dr. Serres resigned on June 13, 2005 as director of the Company and as an officer of the Company on December 26, 2005. Previously, the Lyon Industrial Tribunal had granted Dr. Serres an emergency injunction on October 14, 2003. In consideration for being reinstated by the Company's new management, Dr. Serres agreed in August 2003 to forfeit all legal and punitive compensation for having been terminated by the Company's prior management. Despite this pledge, Dr. Serres maintained his proceeding and on November 3, 2005, the Lyon Industrial Tribunal awarded Dr. Serres the full E173,000 he was seeking, of which approximately E100,000 was payable immediately despite the fact that we immediately appealed the judgment. We have attempted without success to negotiate with Dr. Serres regarding the payments immediately due to him under the judgment. In light of limited financial resources at that time, we did not have enough funds to both pay Dr. Serres the amount immediately due of approximately E100,000 and to initiate new rounds of animal preclinical trials supported by the latest encouraging scientific results. We decided to allocate existing financial resources to the preclinical trials and to contest the judgment of the Lyon Industrial Tribunal based upon advice of our French counsel that the judgment was illegal under French law and that an appeal should be successful. Dr. Serres pursued a strategy of raising pressure on the Company to pay his judgment by seeking to have our subsidiary liquidated through the Tribunal de Commerce in Lyon. He only succeeded in having the company put under a form of receivership ("Redressement Judiciaire"), as previously disclosed on form 10-K for the year ended December 31, 2005 to the Securities and Exchange Commission. We expect to have the company emerge from "Redressement Judiciaire" before January 31, 2007. On June 30, 2006 and on July 5, 2006 respectively, Mymetics filed suit in the Delaware Chancery Court and the New York Supreme Court against its former officers and directors John M. Mussachio and Michael K. Allio, and significant investors, Michael Smith, MFC Merchant Bank, S.A. and KHD Humboldt Wedag International, Ltd., the parent company of MFC, f.k.a. MFC Bancorp, Ltd., alleging breaches of fiduciary duty, interference with prospective business relations and civil conspiracy against one or more of the foregoing parties and seeking monetary damages for these claims. The lawsuits allege that Mymetics is an early stage research oriented company, with early scientific success in developing a vaccine that may prevent the transmission or spread of HIV. The lawsuits also allege that the defendants, former Mymetics officers, directors and investors, have materially jeopardized the future success of Mymetics' ongoing development of an AIDS vaccine by interfering with and frustrating funding opportunities and wasting Mymetics's assets in an effort to control the company for their own personal gain. MFC had recently sent Mymetics a notice of default regarding payment of interest and principal due on a commercial loan addressed in our Form 8-K filed September 8, 2006 While we expect to prevail in these cases, our management believes that an adverse result could have a material adverse effect on our results of operations in future periods. Our wholly owned subsidiary 6543 Luxembourg SA is presently not involved in any litigation incident to our business. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS During the third quarter of 2006, our four officers agreed to convert approximately half of their respective claims against the Company arising out of unpaid salaries, fees and expenses since 2003 for an aggregate 3.5 million restricted common shares at a price of $0.10 per share (current market price was $0.03 per share), resulting in a decrease of our debt of E280,000. During that same third quarter, no shares were issued for services rendered. ITEM 5. OTHER INFORMATION None ITEM 6. EXHIBITS EXHIBIT NUMBER DESCRIPTION ------- ----------- 31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer 31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer 32 Section 1350 Certification of Chief Executive Officer and Chief Financial Officer SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: November , 2006 MYMETICS CORPORATION By: /s/ Christian Rochet ------------------------------------- President and Chief Executive Officer